Stock Market Manager Weekly Update: March 20th, 2023

Weekly Update: March 20th, 2023

Breaking News

Just when you thought all the bad news was out there, here comes another banking crisis.
It seems that every generation of bankers has tunnel vision and little interest in learning from the sins of the past.

Seems like they throw numbers in the billions around to save this bank or that like it was pocket change. When you have banks like SVB and First republic in trouble it’s a clear sign that the fed and its oversight of the banks is either very slipshod or not being done at all.

It’s one thing to count the potential losses in deposits, but quite another to add up the hit to market cap, that is a direct relationship to individual 401K, pension plans and the like since the “banks” are normally considered a “blue chip” place to park your money. If any more major institutions hit the wall, this could get ugly like 08 in a hurry. Get your deposits under the FDIC limits and put the rest under your pillow I guess and hide your head for a while.

Latest on the First Republic bailout….

Inside the $30 billion rescue of First Republic Bank

An 11-bank plan to save First Republic began with a brainstorming session between JPM CEO Jamie Dimon, Fed chair Jerome Powell and Treasury secretary Janet Yellen.

The $30 billion rescue of First Republic Bank began with a series of phone calls Tuesday between JPMorgan Chase CEO Jamie Dimon, Federal Reserve Chair Jerome Powell and Treasury Secretary Janet Yellen.

Dimon was in Washington, according to a person familiar with the events, and he wanted to discuss some issues that concerned bank capital. The subject soon turned to the fate of the nation’s 14th-largest bank.

Check it out here

Corporate News

Sponsored by:

The 21st Century Investment Bank Capital Raises + Strategic Advisory

Donald Capital is a boutique Investment Bank that focuses on raising capital for emerging growth companies in the U.S. and around the globe.

Ideally, we like to work with Private and Public companies with a good management team, a compelling business plan, and the ability to gain market share.

For more information go to: www.DonaldCapital-NY.com

3-15-2023 Can B Corp. (OTC CANB)

Can B Corp. Completes Corporate Debt Restructuring to Position for Uplisting to National Securities Exchange

HICKSVILLE, NY, March 15, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Can B Corp. (OTCQB: CANB) (“Can B” or the “Company”), a health and wellness company specializing in developing, producing, and selling hemp-derived cannabinoid products and durable medical devices, is pleased to announce it has successfully completed a corporate debt restructuring.

Through the restructuring, Can B raised $1.55 million of new capital and extended previously due notes payable totaling $7.0 million to September 1, 2023, and December 31, 2024. Specifically, three Promissory Notes issued to three funds in early 2022 and three Promissory Notes issued to three private investors in late 2022 were restructured to extend maturity dates to late in 2023 to give the Company an additional window to deploy the capital from the new raise.

Read Complete Release

3-6-2023 International Food and Beverage (OTC IFBC)

See the latest investor package. Dino is really getting traction.

https://ifbcorp.com/about-us/

2-15-2023 Antibe Therapeutics, Inc. (OTCQX ATBPF)
Antibe Reports Q3 2023 Interim Financial and Operating Results

– Recent animal data on otenaproxesul’s new formulation confirm rapid drug uptake and potential for effective pain management
– Targeting first clinical dose in calendar Q3 2023; Phase II top-line data within 12 months
– Ended quarter with $42.4 million in cash and equivalents, providing over two years of runway

TORONTO, February 15, 2023–(BUSINESS WIRE)–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, has filed its financial and operating results for the fiscal quarter ended December 31, 2022.

Read Complete Release

1-31-2023 Coeptis Therapeutics, Inc. (OTC COEP)
Coeptis Therapeutics Enters into Sponsored Research Agreement with the University of Pittsburgh to Advance SNAP-CAR Development Program

Coeptis to collaborate with the University of Pittsburgh to expand pre-clinical development of SNAP-CAR T cells targeting HER2-positive cancers

WEXFORD, Pa., Jan. 31, 2023 /PRNewswire/ — Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced a sponsored research agreement with the University of Pittsburgh to advance pre-clinical development of SNAP-CAR T cells targeting HER2 as well as identify opportunities to expand the applicability of SNAP-CAR in oncology. SNAP-CAR, which Coeptis licensed from the University of Pittsburgh, is a multi-antigen chimeric antigen receptor T cell (CAR T) technology that can be adapted to different cancer indications, including hematologic and solid tumors.

Read Complete Release

Alternative Investments

Check out our latest commercial properties including an Amazing Private Island or Resort Development Property in Panama

3700 Acre Private Island in the Las Perlas Islands

7.4 Acre beachfront paradise for development or private retreat

Message me on Linkedin and check our latest commercial listings:

https://www.linkedin.com/in/carldilley/

Please subscribe to our newsletter to get ongoing Real Estate and Alternative Investing updates:

Black Swan Connection Newsletter Signup

March 20, 2023
COMPANY QUOTES, LISTINGS RESEARCH AND NEWS
Coeptis Therapeutics, Inc. Ecrid, Inc (ECDD) Profile
Antibe Therapeutics, Inc (ATBPF) Profile 11/11/2018 News
Can B Corp (CANB) Profile News
Endurance Exploration Group, Ltd (EXPL) Profile 03-26/19 News International Food and Beverage Profile

Déjà vu – Will Tech Stocks and ETFs Crash Again?

March 9, 2023 by Herb Blank

Watching tech stocks lead the market resurgence in the first six weeks of Q1 2023, I was hit with a flash of déjà vu. Just six months ago, the market slaughter of the first six months of 2022 was led by a strong upsurge in the first six weeks of 2022 by beaten-up growth stocks. It didn’t last. Those same stocks led the market back down to new lows between August 16 and September 30. Conversely, when stocks finally surged during parts of the fourth quarter, it was value and high-income stocks that led the comeback as tech stocks continued to flounder.